AN INTERNATIONAL, MULTICENTRIC, PROSPECTIVE, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG ASSOCIATED TO STANDARD OF CARE IN THE TREATMENT OF CLINICAL SYMPTOMS ASSOCIATED WITH INOPERABLE MALIGNANT INTESTINAL OBSTRUCTION
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Lanreotide (Primary)
- Indications Intestinal obstruction
- Focus Therapeutic Use
- Acronyms IMIO
- Sponsors Ipsen
- 30 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.
- 27 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 27 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.